遺伝子治療市場- 世界の産業規模、シェア、動向、機会、予測、ベクタータイプ別、送達方法別、適応症別、地域別、競争別、2020-2030F

遺伝子治療の世界市場規模は2024年に65億4,000万米ドル、予測期間中のCAGRは9.53%で2030年には112億9,000万米ドルに達すると予測されています。

遺伝子治療は、病気の原因である遺伝子の組み合わせの欠損や欠陥を変更、置換、補完することによる病気の治療と説明されています。遺伝子治療は退行性疾患との闘いにおいて最も望ましい研究目標の一つとなっています。遺伝子治療の必要性は、世界中でがんやその他の慢性疾患の症例数が増加していることに後押しされています。遺伝子治療の進歩は今後数年間で承認されると予測されており、予測期間中の遺伝子治療市場の成長に寄与しています。遺伝子治療は、機能不全に陥った遺伝子を不活性化したり、病気の原因となる遺伝子を健康な遺伝子コピーと置き換えたりするなど、遺伝情報を変更することで病気を治療するように設計されています。遺伝子治療は様々な疾患の治療に利用され、その有効性が実証されています。この治療法は糖尿病、がん、心臓病、エイズなどの病気を治すことができます。

遺伝子治療製品の強力なパイプラインが、予測期間中の市場成長を牽引すると予想されます。研究者たちは、遺伝子治療を臨床現場でより利用しやすくするために積極的に取り組んでいます。数多くの大学や研究機関が多様な遺伝子治療製品を開発しており、今後数年間の収益創出に大きく貢献すると予想されます。遺伝子治療の臨床試験数は、FDAによる最初の遺伝子治療の承認後、2017年から2018年にかけて顕著な増加を示しました。米国遺伝子・細胞治療学会（ASGCT）によると、CAR T細胞治療やその他の遺伝子改変細胞治療を含む約1,986の遺伝子治療製品が現在開発中であり、市場拡大をさらに加速させています。

主要市場促進要因

遺伝子研究の進歩

主な市場課題

技術的複雑性

主要市場動向

治療ターゲットの拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 臨床試験分析

第4章 1進行中の臨床試験

第4章 完了した臨床試験2件

第4章 中止された臨床試験3件

第4章 4開発段階別パイプラインの内訳

第4章 5パイプラインのステータス別内訳

第4章 6パイプラインの内訳（研究タイプ別）

第4章 7地域別パイプライン内訳

第4章 8つの臨床試験ヒートマップ

第5章 顧客の声

第6章 世界の遺伝子治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ベクターの種類別（ウイルスベクター、非ウイルスベクター）
  • 投与方法別（体内、体外）
  • 適応症別（希少疾患、がん、神経疾患、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 市場マップ
• ベクトルの種類別
• 配送方法別
• 適応症別
• 地域別

第7章 北米の遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州の遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域の遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米の遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 世界の遺伝子治療市場：SWOT分析

第15章 資金調達分析

第16章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第17章 競合情勢

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche ltd.
• bluebird bio, Inc.
• Novartis AG
• Uniqure N.V.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Gene Therapy Market was valued at USD 6.54 Billion in 2024 and is expected to reach USD 11.29 Billion by 2030 with a CAGR of 9.53% during the forecast period. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market's growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

The strong pipeline of gene therapy products is anticipated to drive market growth over the forecast period. Researchers are actively working to make gene therapy more accessible in clinical settings. Numerous universities and research institutes are developing a diverse range of gene therapy products, which is expected to contribute significantly to revenue generation in the coming years. The number of clinical trials for gene therapy saw a notable increase between 2017 and 2018, following the FDA's approval of the first gene therapy. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell treatments, are currently in development, further accelerating market expansion.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth. For example, in December 2023, the U.S. FDA approved a gene therapy for sickle cell disease, marking the first-ever gene therapy based on CRISPR gene editing. Such groundbreaking advancements and product launches are expected to drive market growth over the forecast period.

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Key Market Players

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche Ltd
• bluebird bio, Inc.
• Novartis AG
• uniQure NV.

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type:

• Viral Vector
• Non-Viral Vector

Gene Therapy Market, By Delivery Method:

• In-Vivo
• Ex-Vivo

Gene Therapy Market, By Indication:

• Rare Diseases
• Cancer
• Neurological Diseases
• Others

Gene Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1 Ongoing Clinical Trials

4.2 Completed Clinical Trials

4.3 Terminated Clinical Trials

4.4 Breakdown of Pipeline, By Development Phase

4.5 Breakdown of Pipeline, By Status

4.6 Breakdown of Pipeline, By Study Type

4.7 Breakdown of Pipeline, By Region

4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.5. By Company (2024)
• 6.3. Market Map
• 6.3.1 By Vector Type
• 6.3.2 By Delivery Method
• 6.3.3 By Indication
• 6.3.4 By Region

7. North America Gene Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Gene Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vector Type
      • 7.3.1.2.2. By Delivery Method
      • 7.3.1.2.3. By Indication
  • 7.3.2. Canada Gene Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vector Type
      • 7.3.2.2.2. By Delivery Method
      • 7.3.2.2.3. By Indication
  • 7.3.3. Mexico Gene Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vector Type
      • 7.3.3.2.2. By Delivery Method
      • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Gene Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vector Type
      • 8.3.1.2.2. By Delivery Method
      • 8.3.1.2.3. By Indication
  • 8.3.2. Germany Gene Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vector Type
      • 8.3.2.2.2. By Delivery Method
      • 8.3.2.2.3. By Indication
  • 8.3.3. United Kingdom Gene Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vector Type
      • 8.3.3.2.2. By Delivery Method
      • 8.3.3.2.3. By Indication
  • 8.3.4. Italy Gene Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vector Type
      • 8.3.4.2.2. By Delivery Method
      • 8.3.4.2.3. By Indication
  • 8.3.5. Spain Gene Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vector Type
      • 8.3.5.2.2. By Delivery Method
      • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Gene Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vector Type
      • 9.3.1.2.2. By Delivery Method
      • 9.3.1.2.3. By Indication
  • 9.3.2. India Gene Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vector Type
      • 9.3.2.2.2. By Delivery Method
      • 9.3.2.2.3. By Indication
  • 9.3.3. Japan Gene Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vector Type
      • 9.3.3.2.2. By Delivery Method
      • 9.3.3.2.3. By Indication
  • 9.3.4. South Korea Gene Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vector Type
      • 9.3.4.2.2. By Delivery Method
      • 9.3.4.2.3. By Indication
  • 9.3.5. Australia Gene Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vector Type
      • 9.3.5.2.2. By Delivery Method
      • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vector Type
      • 10.3.1.2.2. By Delivery Method
      • 10.3.1.2.3. By Indication
  • 10.3.2. Argentina Gene Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vector Type
      • 10.3.2.2.2. By Delivery Method
      • 10.3.2.2.3. By Indication
  • 10.3.3. Colombia Gene Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vector Type
      • 10.3.3.2.2. By Delivery Method
      • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Gene Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vector Type
      • 11.3.1.2.2. By Delivery Method
      • 11.3.1.2.3. By Indication
  • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vector Type
      • 11.3.2.2.2. By Delivery Method
      • 11.3.2.2.3. By Indication
  • 11.3.3. UAE Gene Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vector Type
      • 11.3.3.2.2. By Delivery Method
      • 11.3.3.2.3. By Indication

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. REGENXBIO Inc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Oxford Biomedica PLC.
• 17.3. Voyager Therapeutics Inc.
• 17.4. Human Stem Cells Institute
• 17.5. Dimension Therapeutics, Inc.
• 17.6. Bristol-Myers Squibb Company
• 17.7. Sanofi
• 17.8. F. Hoffmann-La Roche ltd.
• 17.9. bluebird bio, Inc.
• 17.10. Novartis AG
• 17.11. Uniqure N.V.

16. Strategic Recommendations

17. About Us & Disclaimer